Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Memokath 028SW Urethral Stent · 1 trial · 2 indications
| Name | Type | Description |
|---|---|---|
| Memokath 028SW Urethral Stent | DEVICE | - |
Inclusion Criteria: * eligible for prostate seed implant * 50 years of age or older * able to give informed consent Exclusion Criteria: * presence of any other urologic implant, including stents,penile prosthesis or artificial sphincter * history of transurethral resection of prostate (TURP)proce...
Top 20 of 53 competitors
Memokath 028SW Urethral Stent is used to prevent bladder outlet obstruction after prostate implantation for prostate adenocarcinoma. It is placed prophylactically in patients undergoing brachytherapy for prostate cancer to maintain urethral patency and reduce post-procedure urinary complications.
Memokath 028SW Urethral Stent is being developed by Community Health Systems, Inc. (NYSE: CYH). The company is conducting clinical research on this device for use in prostate cancer patients.
Memokath 028SW Urethral Stent is in Phase 1 clinical development. It is an investigational device, not yet approved for commercial use. One Phase 1 trial has been completed to evaluate its safety and feasibility in the intended patient population.
Memokath 028SW Urethral Stent has been studied in one completed clinical trial, NCT00252941. This Phase 1 trial enrolled 20 male patients aged 50 years and older with prostate cancer and post-brachytherapy bladder outlet obstruction. The trial was conducted in the United States.
Memokath 028SW Urethral Stent is not FDA approved. It is an investigational device currently in Phase 1 clinical development. The completed trial was uncontrolled and not randomized, and the device has not yet received regulatory approval for marketing.